News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EpiCept Corporation (EPCT) Receives Scientific Advice from European Medicines Evaluation Agency for AmiKet™ CIPN Program


6/4/2012 11:19:49 AM

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT) today announced that it has received formal scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the clinical and nonclinical development and subsequent Marketing Authorization Approval (MAA) filing of AmiKet™ (amitriptyline 4%, ketamine 2%) for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). AmiKet™ is a topical cream intended for the treatment of peripheral neuropathic pain. In general the CHMP’s requirements are closely aligned with the recent guidance given EpiCept by the U.S. Food and Drug Administration (FDA).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES